| 2023/10/04 10:02:37 | |
|---|---|
| Price | |
| 37.84 EUR | |
| Difference | -0.73% (-0.28) |
General attributes
| ISIN | NL0012169213 |
| Symbol | QGEN |
| Exchange | London Stock Exchange European Trade Reporting |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 8,657 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |
Market data
| Bid (Bid size) | 37.82 EUR (1,000) |
| Ask (Ask size) | 38.07 EUR (1,000) |
| Open | 37.84 EUR |
| High | 37.84 EUR |
| Low | 37.84 EUR |
| Close (prev. day) | 38.12 EUR |
| VWAP | 38.27 EUR |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | 1 |
| Last size | - |
Futures and Options
| Related Futures | 38 |
| Related Options | - |
PDF Downloads
| Annual report: QIAGEN NV |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/10/02 |
|
Aktienempfehlungen Österreich |
|
| 2023/09/29 |
|
Global Equity Ratings |
|
| 2023/09/29 |
|
Aktienempfehlungen Global |
|
| 2023/09/22 |
|
Equity Weekly |
|
| 2023/09/18 |
|
Aktienempfehlungen Österreich |
|
| 2023/10/04 10:02:37 | |
|---|---|
| Price | |
| 37.84 EUR | |
| Difference | -0.73% (-0.28) |
General attributes
| ISIN | NL0012169213 |
| Symbol | QGEN |
| Exchange | London Stock Exchange European Trade Reporting |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 8,657 EUR |
| Benchmark | AMSTERDAM EXCHANGES INDEX |
Market data
| Bid (Bid size) | 37.82 EUR (1,000) |
| Ask (Ask size) | 38.07 EUR (1,000) |
| Open | 37.84 EUR |
| High | 37.84 EUR |
| Low | 37.84 EUR |
| Close (prev. day) | 38.12 EUR |
| VWAP | 38.27 EUR |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | 1 |
| Last size | - |
Performance and Risk
| 6M | 1Y | 3Y | |
| Perf (%) | -8.26% | -11.07% | -13.58% |
| Perf (abs.) | -3.43 | -4.75 | -5.99 |
| Beta | 0.60 | 0.54 | 0.40 |
| Volatility | 16.35 | 20.15 | 24.41 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 37.91 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 39.32 EUR (4,261) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 40.93 EUR (11,672) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 43.07 EUR (15,406) |
| YTD High | date | 47.78 EUR (2023/01/04) |
| YTD Low | date | 36.87 EUR (2023/09/25) |
| 52 Weeks High | date | 47.93 EUR (2022/12/13) |
| 52 Weeks Low | date | 36.87 EUR (2023/09/25) |
All listings for QIAGEN NV
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2023/10/04 | 16:35 | 37.96 EUR | 5.66 | 1,343 |
| Vienna Stock Exchange | 2023/10/04 | 09:05 | 37.86 EUR | 0.00 | 1 |
| Tradegate | 2023/10/04 | 14:53 | 37.92 EUR | 0.07 | 13 |
| Stuttgart | 2023/10/04 | 16:30 | 37.86 EUR | 0.00 | 94 |
| SIX Swiss Exchange | 2019/06/28 | 17:35 | 39.45 CHF | 0.00 | 1 |
| NYSE | 2023/10/04 | 16:35 | 39.855 USD | 12.23 | 2,913 |
| Munich | 2023/10/04 | 08:02 | 38.10 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2023/10/04 | 10:02 | 37.84 EUR | 0.00 | 1 |
| Hanover | 2023/10/04 | 08:16 | 37.60 EUR | 0.00 | 1 |
| Hamburg | 2023/10/04 | 08:16 | 37.59 EUR | 0.00 | 1 |
| Frankfurt | 2023/10/04 | 15:31 | 37.81 EUR | 0.00 | 3 |
| Duesseldorf | 2023/10/04 | 16:31 | 37.85 EUR | 0.00 | 4 |
| Berlin | 2023/10/04 | 08:03 | 37.83 EUR | 0.00 | 1 |
| BX Swiss | 2023/05/09 | 18:00 | 40.514 CHF | 0.00 | 1 |
Company Logo
Contact Details
| QIAGEN NV |
| - - |
| Hulsterweg 82 - 5912 PL Venlo |
| Telefon: +31-77-355-66-00 |
| Fax: +31-77-355-66-58 |
| E-mail: qiagen@qiagen.com |
PDF Downloads
| Annual report: QIAGEN NV | |
Company Profile
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands. |
Members of Management Board
| Thierry Bernard | Chairman of Managing Board |
| Barthold Piening | Member of Executive Committee |
| Jonathan Sheldon | Member of Executive Committee |
| Thomas Schweins | Member of Executive Committee |
| Jean-Pascal Viola | Member of Executive Committee |
| Roland Sackers | Member of Executive Committee |
| Stephany Foster | Member of Executive Committee |
Board of directors
| Lawrence Rosen | Chairman of Supervisory Board |
| Elaine Mardis | Member of Supervisory Board |
| Eva Pisa | Member of Supervisory Board |
| Metin Colpan | Member of Supervisory Board |
| Ross Levine | Member of Supervisory Board |
| Toralf Haag | Member of Supervisory Board |
| Elizabeth Tallett | Member of Supervisory Board |
| Stephen Rusckowski | Member of Supervisory Board |
| Thomas Ebeling | Member of Supervisory Board |